Novartis has signed a global licensing agreement with Arrowhead Pharmaceuticals for the preclinical RNA interference (RNAi) therapy ARO-SNCA, targeting alpha-synuclein in Parkinson’s disease and related disorders. The deal, announced Tuesday and reported by Reuters, includes a $200 million upfront payment to Arrowhead, with up to $2 billion in potential milestones, plus tiered royalties (capped in…
Menarini and Insilico ink $550M deal for AI-discovered cancer therapy
Second collaboration builds on rapid progress of AI-designed KAT6 inhibitor licensed in 2024 Agreement includes $20 million upfront payment with potential total value exceeding $550 million plus tiered royalties New preclinical asset demonstrates broad anti-tumor activity across multiple solid tumor types Less than a year after their first collaboration, pharmaceutical giant Menarini Group and AI-driven…